soul trial oral semaglutide cardiovascular outcomes 2024 results nejm SOUL: Bests Usual Care in High-Risk Type 2 Diabetes The Role of Glucagon-Like Peptide-1

Glucagon-like Peptide-1 (GLP-1) Agonists Market Trends Steady Growth : The global GLP-1 Receptor Agonist Market is set to witness steady growth, forecast to be a $100 Billion market by 2030

[22] [23] Versus DPP-4 inhibitors (such as sitagliptin), GLP-1 receptor agonists produce greater HbA1c reductions and weight loss, with some offering proven cardiovascular benefits

For patients and healthcare providers, the appeal is clear: retatrutide may finally address the full spectrum of metabolic dysfunctionfrom obesity and diabetes to fatty liver diseaseoffering a treatment option that is both broader in scope and more powerful in effect

Not everyone responds to tirzepatide in the same way

PMID: 40728138 | doi:10.1515/jbcpp-2025-0113 Giblin K et al

doi: 10.1186/s12967-024-04927-z 52 FerrulliAMacrCTerruzziIMassariniSAmbrogiFAdamoMet al